Page History

Kent Goklen is the Director of Downstream Process Development at GlaxoSmithKline Biopharm R&D in King of Prussia, PA, with responsibility for the process development, scale-up and tech transfer of purification processes for biopharmaceuticals. Kent joined GSK in 2008, after retiring from the Merck Research Laboratories, where he had led a team in the BioProcess R&D organization. While at Merck, he played a key role in the development and demonstration of processes for Mevacor/Zocor^TM and Cancidas.^® Kent has a B.S. from Cornell University and M.S. and Ph.D. degrees from MIT, all in Chemical Engineering. Kent is a Fel- low of the American Chemical Society, where he is active in the Division of Biochemical Technology, and is Adjunct Professor of Chemical and Biomolecular Engineering at Cornell University.